Showing 1 to 3 of 3 results


Spain Investigates Novo Nordisk for Potentially Illegal Weight-Loss Drug Advertising
Spain is investigating Novo Nordisk for potentially illegal advertising of its weight-loss drugs Ozempic and Wegovy, following similar accusations in Ireland and the UK, prompting concerns about pharmaceutical marketing tactics and their impact on national health budgets.
Spain Investigates Novo Nordisk for Potentially Illegal Weight-Loss Drug Advertising
Spain is investigating Novo Nordisk for potentially illegal advertising of its weight-loss drugs Ozempic and Wegovy, following similar accusations in Ireland and the UK, prompting concerns about pharmaceutical marketing tactics and their impact on national health budgets.
Progress
48% Bias Score


McKinsey Pays $650 Million to Settle Opioid Marketing Case
McKinsey & Company will pay $650 million to settle US claims that it helped market opioid painkillers, including advising Purdue Pharma on boosting OxyContin sales; a former McKinsey partner will plead guilty next month, and the firm is prohibited from opioid marketing for five years.
McKinsey Pays $650 Million to Settle Opioid Marketing Case
McKinsey & Company will pay $650 million to settle US claims that it helped market opioid painkillers, including advising Purdue Pharma on boosting OxyContin sales; a former McKinsey partner will plead guilty next month, and the firm is prohibited from opioid marketing for five years.
Progress
36% Bias Score

Novo Nordisk's Obesity Campaign Backfires Amidst Public Outrage
Novo Nordisk's Madrid campaign, labeling obesity a deadly disease, sparked controversy due to its aggressive tone and perceived promotion of Ozempic, despite support from some scientific societies who now express concern.

Novo Nordisk's Obesity Campaign Backfires Amidst Public Outrage
Novo Nordisk's Madrid campaign, labeling obesity a deadly disease, sparked controversy due to its aggressive tone and perceived promotion of Ozempic, despite support from some scientific societies who now express concern.
Progress
60% Bias Score
Showing 1 to 3 of 3 results